Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Int J Tuberc Lung Dis ; 28(9): 439-445, 2024 Sep 01.
Article in English | MEDLINE | ID: mdl-39187998

ABSTRACT

BACKGROUNDThe impact of severe COVID-19 pneumonia on healthcare systems highlighted the need for accurate predictions to improve patient outcomes. Despite the established efficacy of glucocorticoids (GCs), variable patient responses are observed, and the existing clinical scores are limited in predicting non-responders. We propose a machine learning (ML) based approach to predict mortality in COVID-19 pneumonia treated with GCs.METHODSThis is an ML-driven retrospective analysis involving 825 patients. We leveraged XGBoost to select the most appropriate features from the initial 52, including clinical and laboratory data. Six different ML techniques were compared. Shapley additive explanation (SHAP) values were used to describe the influence of each feature on classification. Internal validation was performed.RESULTSNine key predictors of death were identified: increasing C-reactive protein (CRP), decreasing arterial partial pressure of oxygen to fraction of inspired oxygen ratio (PaO2/FiO2), age, coronary artery disease, invasive mechanical ventilation, acute renal failure, chronic heart failure, PaO2/FiO2 earliest value, and body mass index. Random forest achieved the highest test area under the receiver operating characteristic curve at 0.938 (95% CI 0.903-0.969). SHAP values highlighted age and PaO2/FiO2 improvement as the most influential features; the latter showed a higher impact than CRP reduction over time.CONCLUSIONThe proposed ML algorithm effectively predicts the risk of hospital death in COVID-19 pneumonia patients undergoing GCs. This approach can be adapted to datasets measuring similar clinical variables..


Subject(s)
COVID-19 Drug Treatment , COVID-19 , Glucocorticoids , Machine Learning , Humans , Retrospective Studies , Male , Glucocorticoids/therapeutic use , Glucocorticoids/administration & dosage , Female , COVID-19/mortality , Middle Aged , Aged , Severity of Illness Index , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL